Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

54.52 -1.64 (-2.92%)
Streaming Delayed Price Updated: 3:03 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
CRISPR Therapeutics shares have soared 39% over the past three months. 
Via The Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough. 
Via The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
Discover the trailblazing strategies of three tech stocks that are reshaping industries through innovation, adaptability and revenue surges. 
Via InvestorPlace
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
Via Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
These risky stocks can deliver big returns for investors. 
Via The Motley Fool
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
Key regulatory developments sent this biotech stock higher. 
Via The Motley Fool
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
An acquisition could be both a blessing and a curse for long-term investors. 
Via The Motley Fool
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
My 3 Highest-Conviction Growth Stocks to Buy in 2024
Simply put, these stocks inspire confidence. 
Via The Motley Fool
My 5 Top Growth Stocks to Buy Hand Over Fist for 2024
2024 could be a year of growth. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
3 Cathie Wood Stocks to Start Off Your New Year Right
The following stocks could deliver big gains over time. 
Via The Motley Fool
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
You'll find exciting innovators across industries. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.